2021年南模生物业绩实现快速增长
营业收入2.75亿元，同比增长40.31%
归母净利润0.61亿元，同比增长36.59%
扣非后归母净利润0.52亿元，同比增长60.36%
总资产19.64亿元，比上年同期末增长450.13%
研发投入0.48亿元，占营业收入17.42%，同比增长39.31%
具体请观看《2021南模生物年报速读》视频版
关于我们
上海南方模式生物科技股份有限公司（Shanghai Model Organisms Center, Inc.，简称"南模生物"），成立于2000年9月，始终以编辑基因、解码生命为己任，专注于模式生物领域，专业从事遗传修饰动物模型的研发、饲养繁育和分析检测，拥有模型定制、饲养繁育、表型分析、药理药效服务等七大核心平台。其中药理药效服务平台目前主要聚焦肿瘤、自身免疫疾病和罕见病三大领域，依托于模型服务平台，已经建立了全面的体内和体外药理药效服务体系，并为广大客户提供符合国际水平的服务。
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreSMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn more
